How far is psilocybin from becoming a covered treatment?

THE DISPATCH

The U.S. federal government moved faster on psychedelic medicine in a single week of April 2026 than it had in the preceding five decades. On April 18, President Trump signed an executive order directing federal agencies to accelerate development and access to serotonin 2A agonist therapies for serious mental illness. Six days later, the FDA issued Commissioner's National Priority Vouchers (CNPV) to three programs: Compass Pathways' synthetic psilocybin (COMP360) for treatment-resistant depression, the Usona Institute's synthetic psilocybin (PSIL102) for major depressive disorder, and Transcend Therapeutics' methylone for PTSD. The vouchers compress FDA review time to as little as one to two months after submission¹ ², a major shift from the six to ten month review process.

In this issue:

→ What a priority voucher actually means, and what still stands between FDA approval and a covered patient treatment

→ What the evidence tells patients about realistic timelines, and what the headlines are leaving out

→ The VA expansion, a new state law, and where the access picture stands right now

---

THE SCIENCE

On April 24, 2026, the FDA announced priority review vouchers for three psychedelic medicine programs, the direct result of President Trump's executive order signed six days earlier.² The move compresses the FDA's standard six-to-ten-month review period to approximately one to two months after a New Drug Application is submitted. Compass Pathways' rolling NDA submission is on track for Q4 2026 and with the CNPV, an approval decision could follow within weeks of that filing.

The headlines covering this have been encouraging. Most of them are also incomplete.

What the executive order does: it directs the FDA to prioritize review of breakthrough-designated psychedelic compounds, allocates $50 million for federal-state research collaboration, and instructs the DEA to reduce restrictions on approved research. What it does not do is change the Schedule I status of psilocybin, approve any compound for medical use, or open a pathway for insurance reimbursement. Those outcomes require entirely separate processes, each with its own timeline.

The path from "priority voucher" to "covered patient treatment" runs through several gates, and FDA approval is one of them. After approval, the DEA must separately reschedule the approved formulation from Schedule I, a process the DEA is required to initiate within 90 days of approval, though the full rescheduling timeline can extend beyond that window. After rescheduling, billing and coding bodies must assign billing codes (CPT, ICD-10, and HCPCS) before insurers can process claims. The reimbursement infrastructure does not yet exist for psilocybin-assisted therapy. Each gate requires its own action. The priority voucher accelerates passage through only one of them.³

For a patient with treatment-resistant PTSD or depression in mid-2026, the practical picture is this: in Oregon and Colorado, state-regulated programs are operating now, open to any adult 21 and older, without a prescription or diagnosis. New Jersey signed a hospital-based pilot into law in January 2026 with $6 million in state funding.⁴ These pathways are legal and functioning. They are also entirely out of pocket, ranging from $1,000 to $5,000 per session, with no insurance coverage available anywhere in the United States.

Federally approved, insurance-covered psilocybin-assisted therapy, the scenario that would reach the most patients, remains at least 18 months away, contingent on each step proceeding without delay.

The federal movement reflects an evidence base that has been building for years: two consecutive positive Phase 3 trials for treatment-resistant depression, Phase 2 PTSD safety data published in 2026 with no serious adverse events,⁵ and a Lancet qualitative study documenting how patients describe the experience.⁶ The executive order represents the most significant federal signal in this space since psilocybin was classified as Schedule I in 1970. But a signal is not a system.

Understanding exactly where the system is and is not moving is what allows patients, clinicians, and families to plan accurately, and to advocate for the specific steps that remain unfinished. The question is no longer whether psilocybin-assisted therapy reaches patients at scale, but which patients, through which systems, on what timeline, and whether the infrastructure will be built fast enough to meet the moment that approval creates.

---

THE STORY

In a December 2025 qualitative study published in eClinicalMedicine, part of The Lancet, researchers conducted in-depth interviews with participants enrolled in a Phase 2 psilocybin PTSD trial across three clinical sites in the United States and United Kingdom.⁶ Participants described something the quantitative data does not fully capture: the experience of being able to approach traumatic memory without being overtaken by it. One participant described it as engaging with the trauma "like watching something from the outside rather than being inside it again."

That account reflects a clinically meaningful shift in trauma processing, one the research consistently associates with symptom reduction rather than avoidance. The care pathway that would make experiences like it routine for most patients in the United States does not yet exist.

The clinical research documenting outcomes like these is accelerating. The system for delivering those outcomes at scale, trained therapists, billing infrastructure, and covered access, is still being built. That is the specific gap this regulatory moment has the capacity to close.

What is moving: Compass's NDA on track for Q4 2026, nine VA facilities now running multi-year psychedelic-assisted therapy studies, and New Jersey's pilot program funded and operational. Watch for DEA rescheduling guidance and the first billing code proposals in the months following FDA approval. The good news is the pharma companies aren't starting from scratch. The 2019 approval and launch of SPRAVATO (esketamine), a previously Schedule I compound, for treatment-resistant depression gives a rough blueprint for navigating the steps to ensure patient access after FDA approval is obtained.

---

ON OUR RADAR

① Trump's Executive Order: What It Changed, and What It Didn't On April 18, 2026, President Trump signed an executive order directing the FDA to prioritize psychedelic compound review, allocating $50M for federal-state research, and instructing the DEA to reduce research restrictions. Six days later, three programs received Commissioner's National Priority Vouchers, the fastest federal follow-through on psychedelic policy in the field's history. The Schedule I designation for psilocybin is unchanged. The federal direction is clearly supportive of making progress in this space.¹ ²

② Phase 2 PTSD Safety Trial Published: Single Dose, No Serious Adverse Events A nonrandomized open-label Phase 2 trial published in 2026 in the Journal of Psychopharmacology enrolled 22 participants with PTSD and administered a single dose of psilocybin. No serious adverse events. Clinically meaningful reduction in CAPS-5 symptom severity scores. Most adverse events resolved within 24 hours. This is a small, preliminary sample and the confirmatory Phase 3 evidence base is still developing, but the safety profile continues to hold.⁵

③ New Jersey Signs State Pilot Program, Expanding Legal Access Map In January 2026, New Jersey signed a psilocybin therapy pilot program into law with $6 million in hospital-based state funding, the first hospital-embedded model at the state level. Oregon and Colorado remain the only full regulatory frameworks. 26 states are now considering psilocybin legislation. The state-level access map is widening faster than federal approval timelines.⁴

---

YOU ASKED

Q: "If psilocybin gets FDA approval, does that mean my insurance will cover it?"

Not automatically, and the distinction matters for anyone making decisions now. FDA approval establishes that a drug is safe and effective for a specific indication. It does not create a covered benefit. For insurance reimbursement to follow, the DEA must first reschedule the approved formulation from Schedule I. After rescheduling, billing bodies must assign billing codes before insurers can process claims, and individual insurers must then decide whether to include the therapy in their formularies. The realistic estimate for a covered psilocybin-assisted therapy session under standard insurance is likely 2028, under an optimistic scenario. In the meantime, state-regulated programs in Oregon, Colorado, and New Jersey offer legal access today, entirely out of pocket. If you are a patient or family member evaluating options, that distinction, legal access now versus covered access later, is the most important thing to understand before making any plan.

---

This week's takeaway: when reading about the FDA's priority vouchers, focus on one question. Which gate is being accelerated, and which ones remain? The voucher compresses the review timeline. The access pathway has several more steps. Knowing which step is the bottleneck is what allows patients and families to plan with accuracy.

A question worth sitting with: what would it mean for patients with treatment-resistant PTSD if the infrastructure gap, insurance coverage, trained therapists, accessible clinics, closed at the same pace as the evidence?

Read the FDA's priority voucher announcement directly: Compass Pathways — FDA NDA Rolling Review and Priority Voucher

— Jama Pitman

CEO, Rose Hill Life Sciences

Advancing the development of novel psychedelic-based therapeutics

---

FOOTNOTES

¹ White House. "Accelerating Medical Treatments for Serious Mental Illness." Presidential Actions, April 18, 2026. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/

² Compass Pathways. "Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher." IR.CompassPathways.com, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx

³ Managed Healthcare Executive. "FDA grants priority vouchers to 3 psychedelic medications." 2026. https://www.managedhealthcareexecutive.com/view/fda-grants-priority-vouchers-to-3-psychedelic-medications

⁴ Psychedelic Alpha. "Psychedelic Laws — State Tracker." https://psychedelicalpha.com/data/psychedelic-laws

⁵ McGowan, N.M., Rucker, J.J., Yehuda, R., et al. "Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial." Journal of Psychopharmacology, 2026. https://pubmed.ncbi.nlm.nih.gov/40883964/

⁶ McGowan, N.M., et al. "Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment." eClinicalMedicine (The Lancet), December 2025. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00626-1/fulltext

---

The Rose Hill Review